

1 **Resistance to critically important antibiotics in hospital wastewater**
2 **from the largest Croatian city**

3
4 Ana Puljko^a, Svjetlana Dekić Rozman^{a,1}, Ivan Barišić^b, Ana Maravić^c, Marko Jelić^d, Ivana
5 Babić^a, Milena Milaković^a, Ines Petrić^a, Nikolina Udiković-Kolić^{a, *}

6
7 ^a Division for Marine and Environmental Research, Ruđer Bošković Institute, Bijenička 54,
8 P.O. Box 180, 10 002 Zagreb, Croatia

9 ^b Molecular Diagnostics, Austrian Institute of Technology, Giefinggasse 4, 1210 Vienna,
10 Austria

11 ^c Department of Biology, Faculty of Science, University of Split, Ruđera Boškovića 33, 21 000
12 Split, Croatia

13 ^d Department of Clinical Microbiology, University Hospital for Infectious Diseases,
14 Mirogojska 8, 10 000 Zagreb, Croatia

15
16
17 * Corresponding author:

18 Dr. Nikolina Udiković-Kolić (nudikov@irb.hr)

19 Division for Marine and Environmental Research

20 Ruđer Bošković Institute

21 Bijenička 54, P.O. Box 180; 10 002 Zagreb, Croatia

22 E-mail address: nudikov@irb.hr

23
24 ¹Present address: University of Helsinki, Viikinkaari 9, 00140 Helsinki, Finland

25 **ABSTRACT**

26 The emergence of extended-spectrum β -lactamase (ESBL)- and especially carbapenemases in
27 *Enterobacterales* has led to limited therapeutic options. Therefore, it is critical to fully
28 understand all potential routes of transmission, especially in high-risk sources such as hospital
29 wastewater. Wastewater samples were collected from two major hospitals in Zagreb during
30 winter and summer 2020. Conventional culturing was performed to quantify coliform bacteria,
31 and quantitative PCR was performed to monitor two ESBL and five carbapenemase (CP) genes,
32 and four enteric opportunistic pathogens (EOPs) in the collected samples. The average
33 concentrations of total, presumptive ESBL- and carbapenem-resistant coliforms for all samples
34 combined were 3.4×10^4 , 4.7×10^3 and 1.8×10^4 CFU/mL, respectively. The most abundant
35 resistance gene was *bla*_{KPC} (up to 10^{-1} gene copies/16S copies). *E. coli* was the most prevalent
36 among EOPs (10^5 cell equivalents/mL). Sixty-nine ESBL- and 90 carbapenemase-producing
37 *Enterobacterales* (CPE) isolates were isolated from hospital wastewater. All were multidrug-
38 resistant and were mostly identified as *Escherichia coli*, *Citrobacter*, *Enterobacter*, and
39 *Klebsiella*. Among ESBL isolates, *bla*_{CTX-M-15} was the most prevalent ESBL gene, whereas in
40 CPE isolates, *bla*_{KPC-2} and *bla*_{NDM-1} were the most frequently detected CP genes, followed by
41 *bla*_{OXA-48}. Molecular epidemiology using PFGE, MLST and whole-genome sequencing (WGS)
42 revealed that clinically relevant variants such as *E. coli* ST131 (*bla*_{CTX-M-15}/*bla*_{TEM-116}) and
43 ST541 (*bla*_{KPC-2}), *K. pneumoniae* ST101 (*bla*_{OXA-48}/*bla*_{NDM-1}), and *Enterobacter cloacae*
44 complex ST277 (*bla*_{KPC-2}/*bla*_{NDM-1}) were among the most frequently detected bacterial strains.
45 WGS also revealed that these isolates contained resistance genes to multiple antibiotic classes
46 and a diverse plasmidome. The *bla*_{CTX-M}, *bla*_{OXA-48}, and *bla*_{KPC-2} genes were found to be
47 associated with mobile genetic elements, particularly transposons and insertion sequences,
48 suggesting the potential for mobilization. Our findings suggest the need to ensure effective

49 treatment of hospital wastewater to reduce or prevent the spread of critical priority pathogens
50 and resistance genes into water systems.

51

52

53 **Keywords:** antibiotic resistance; hospital wastewater, carbapenemase, ESBL,

54 *Enterobacterales*, multidrug

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88 **1. Introduction**

89

90 The threat of increasing antibiotic resistance (AR) of pathogenic bacteria is one of the
91 greatest challenges to global health. Of particular concern is the increasing bacterial resistance
92 to β -lactam antibiotics such as 3rd generation cephalosporins and carbapenems, which are
93 classified as "critically important for human medicine" by the World Health Organization
94 (WHO) (WHO, 2019). It is particularly important to protect the efficacy of these and other
95 antibiotics used as a last-resort, as their loss due to AR would result in treatment failures and
96 deaths.

97 Hospital wastewater is considered a high-risk point source for the spread of antibiotic-
98 resistant bacteria (ARB), antibiotic-resistance genes (ARGs), and enteric opportunistic
99 pathogens (EOPs) in the environment (Hassoun-Kheir et al., 2020). Hospitalized patients are
100 more likely to be treated with antibiotics than the general population, and therefore, higher
101 concentrations of ARB or ARGs are often found in hospital wastewater than in municipal
102 wastewater (Hassoun-Kheir et al., 2020; Paulus et al., 2019). These ARB/ARGs can spread to
103 rivers and lakes through municipal wastewater treatment plants (WWTPs) because they are not
104 always completely removed in WWTPs (Kehl et al., 2022; Puljko et al., 2022). Human-derived
105 bacteria that do not persist in the aquatic environment can transfer ARGs to resident aquatic
106 microorganisms, including pathogens, through horizontal gene transfer (HGT) (Gonzalez-Plaza
107 et al, 2019; Larsson and Flach, 2022). This could lead to further potential transfer of ARGs
108 from the environment to humans. Therefore, it is important to understand the AR gene pool of
109 hospital wastewater, especially for bacteria of the order *Enterobacterales*, some of which are
110 important nosocomial pathogens that can thrive in both the environment and the human gut, in
111 order to track their spread from the hospital point source to the environment.

112 In contrast to many developed countries, hospital wastewater in Croatia is discharged
113 directly into municipal WWTPs without any treatment, which may be a cause for concern, even

114 though hospital wastewater represents only a small proportion (less than 2%) of the total volume
115 of wastewater treated in WWTP. Therefore, ARB/ARGs, which are typically found in low
116 levels in wastewater, such as CP-producing *Enterobacterales* (CPE) and their mobile ARGs
117 (e.g. *bla*_{KPC}, *bla*_{NDM}, *bla*_{OXA-48}, *bla*_{VIM} and *bla*_{IMP}), can spread rapidly and widely, posing a
118 greater risk than other, more common environmental bacteria with intrinsic resistance
119 mechanisms (Manaia et al., 2018). CPE and ESBL (extended spectrum β -lactamase)-producing
120 *Enterobacterales* (ESBL-E) have been listed by the WHO as critical priority pathogens for
121 which research and the development of new antibiotics is urgently needed due to the emergence
122 of multidrug resistance among these pathogens (WHO, 2017). In Europe, these species have
123 been increasingly detected in clinical samples over the past decade (Kazmierczak et al., 2021).
124 Croatia is one of the countries with a high prevalence of these strains, especially *Klebsiella*
125 *pneumoniae* isolates (62% resistant to 3rd generation cephalosporins in 2021; ECDC, 2021). In
126 addition, carbapenem resistance rates among clinical *K. pneumoniae* isolates increased from
127 2% in 2018 to 32.9% in 2021 in Croatia (ECDC, 2021). Previous studies have identified hospital
128 wastewater as a high-risk point source for the spread of CPE and ESBL-E (Jelić et al., 2019;
129 Kehl et al., 2022). However, more information on their phylogeny and genomic characteristics
130 is needed to better assess the risk of spreading these clinically important ARB and their ARGs
131 via hospital wastewater.

132 The most common resistance mechanism to β -lactams in *Enterobacterales* is the
133 production of β -lactamases, and the most important enzymes in this family are the ESBLs,
134 plasmid-mediated AmpC β -lactamases (pAmpC), and carbapenemases (CPs). ESBLs confer
135 resistance to most β -lactam antibiotics, including penicillins, cephalosporins, and monobactam
136 aztreonam, and the most common variants are TEM, SHV, CTX-M, and OXA (Bradford,
137 2001). pAmpC enzymes are generally less prevalent than ESBLs in *Enterobacterales*, but are
138 still important because they contribute to β -lactam resistance, which can also extend to

139 carbapenems when pAmpC are overproduced in combination with an impermeability defect
140 (Barišić et al., 2014). Carbapenems are considered to be a last-resort treatment for Gram-
141 negative infections, as they retain activity against chromosomal cephalosporinases and ESBLs.
142 The production of CPs can confer resistance to virtually all β -lactams and is the most common
143 mechanism of resistance to carbapenems among Gram-negative bacteria. Acquired CPs of
144 clinical importance include KPC, VIM, NDM, IMP and OXA-48, and their geographic
145 distribution is remarkably diverse (Nasri et al., 2017; Kazmierczak et al., 2021; Neidhöfer et
146 al., 2021).

147 The aim of this study was to investigate the prevalence of *Esherichia coli* and other
148 coliforms presumed to be ESBL- or carbapenemase-positive, as well as selected ESBL and CP
149 genes and EOPs in wastewater from two hospitals in Zagreb using culture-based and molecular
150 methods (real-time PCR). A total of 159 enterobacterial isolates (69 ESBL- and 90 CP-
151 producing) was successfully isolated and identified. These isolates were characterized by
152 phenotypic and genotypic assays to determine their AR profiles, molecular epidemiology, and
153 ARGs present in them. In addition, the mechanisms of AR and their potential mobility in the
154 selected isolates of *E. coli*, *Klebsiella* spp., and *Enterobacter cloacae* complex were characterised
155 using whole genome sequencing.

156

157 **2. Materials and methods**

158 **2.1. Sample collection**

159
160 Untreated wastewater samples were collected from two large hospitals (abbreviated as H1
161 and H2) in Zagreb, Croatia. Both hospitals provide primary health care and emergency services
162 and differ in the number of hospital beds (H1 – 1510 beds, and H2 – 570 beds). Samples were
163 taken at three time points in winter (January) and summer (July) of 2020. Grab wastewater
164 samples (2000 mL) were collected from the sewer system in sterile 2.5 L glass bottles before
165 being discharged into the municipal sewer system. Hospital wastewater is not treated at the
166 hospital before it enters the municipal sewers, as is common for all hospitals in Croatia. The
167 collected samples were transported on ice in cool boxes to the laboratory and processed within
168 2 hours.

169

170 **2.2. DNA extraction and real-time PCR (qPCR) assays**

171 For DNA extraction from wastewater, triplicate subsamples (50 - 90 mL) were filtered
172 through mixed cellulose ester membranes (47 mm diameter, 0.22 µm pore size, GE Healthcare,
173 Life Science, USA). Total community DNA was extracted from the filters using the DNeasy
174 Powersoil kit (Qiagen, USA) according to the manufacturer's recommendations. Before the
175 extraction procedure, the filters were cut into small pieces with sterile scissors. DNA quality
176 (260/280 ratio) was determined using a Nanodrop spectrophotometer (BioSpec Nano,
177 Shimadzu, Japan), and DNA quantity was determined using a Qubit Fluorometer 3.0 (Thermo
178 Fisher Scientific, USA). All extracts were stored at -20 °C until use.

179 qPCR was used to quantify two ESBL genes (*bla*_{TEM} and *bla*_{CTX-M-32}), five CP genes
180 (*bla*_{KPC-3}, *bla*_{NDM}, *bla*_{OXA-48-like}, *bla*_{IMP}, and *bla*_{VIM}), colistin resistance gene (*mcr-1*), and the
181 16S rRNA gene (*rrn*) as a marker for total bacteria. In addition, marker genes for EOPs were
182 also quantified: *yccT* (*E. coli*), *gltA* (*K. pneumoniae*), *secE* (*Acinetobacter baumannii*) and 23S
183 rDNA (enterococci). Primers, qPCR conditions and generation of standard curves are as

184 described in Puljko et al. (2022). All qPCR assays were performed on the ABI 7300 real-time
185 PCR thermocycler (Applied Biosystems, USA) with Power SYBR® Green PCR Master Mix
186 (10 µL, Applied Biosystems, USA), 1 µM of each primer (Puljko et al., 2022, Table S1, Table
187 S2), and 2 ng of DNA template in a total volume of 20 µL. Gene abundances were calculated
188 per 1 mL sample (absolute abundance) and per number of *rrn* copies (relative abundance). The
189 abundances of the *yccT* gene of *E. coli*, the *gltA* gene of *K. pneumoniae*, *secE* gene of *A.*
190 *baumannii*, the 23S rRNA gene of enterococci, and the *rrn* gene of total bacteria were expressed
191 as cell equivalents (CE)/mL. In the case of *E. coli*, *K. pneumoniae*, and *A. baumannii*, only one
192 copy of the target gene is present in a cell (Clifford et al., 2012; Gadsby et al 2015); thus, one
193 copy number is equivalent to one cell. However, in enterococci and total bacteria, average copy
194 number of 23S rRNA and 16S rRNA genes is five and three, respectively (Stoddard et al 2015);
195 therefore, 23S rRNA and 16S rDNA copies determined by qPCR were divided by 5 and 3,
196 respectively, to convert them to CE.

197

198 **2.3. Coliform counts and isolation of ARB**

199 To enumerate *E. coli* and non-*E. coli* coliforms, a series of dilutions of wastewater samples
200 were prepared in 0.85% NaCl (tenfold dilutions up to 1:10,000), and then filtered in triplicate
201 through sterile mixed cellulose ester membrane filters (47 mm diameter, 0.22 µm pore size,
202 Whatman, GE Healthcare, Life Science, SAD). Filters were then placed on 1) Rapid'*E.coli* 2
203 (Bio-Rad, France) for enumeration of total *E. coli* and non-*E. coli* coliforms; 2) Rapid'*E.coli* 2
204 agar plates supplemented with 4 mg/L cefotaxime (CTX) representing 3rd generation
205 cephalosporins for enumeration of CTX-resistant (CTX-R) *E. coli* and non-*E. coli* coliforms
206 and 3) CHROMagar mSuperCARBA (CHROMagar, France) agar plates for enumeration of
207 carbapenem-resistant (CR) *E. coli* and non-*E. coli* coliforms. Plates were incubated at 37°C for
208 24 h, and colonies of total, CTX-R and CR *E. coli* and non-*E. coli* coliforms were enumerated,

209 and their concentrations were calculated as colony-forming units (CFU) per milliliter of
210 wastewater (CFU/mL).

211 For isolation of ARB, a total of 200 colonies of presumptive *E. coli* and other coliforms
212 were picked from Rapid'*E. coli* 2 with CTX and CHROMagar mSuperCARBA plates and re-
213 streaked on the same medium to purity. The purified colonies were stored in a 20% glycerol
214 stock at -80°C .

215

216 **2.4. Identification of isolates**

217 Bacterial isolates were sent to the Laboratory for Mass Spectrometry and Functional
218 Proteomics at the Ruđer Bošković Institute for identification using Matrix Assisted Laser
219 Desorption Ionization – Time of Flight Mass Spectrometry (MALDI-TOF MS) analysis.
220 Isolates were streaked on Mueller-Hinton plates (Oxoid, UK) and incubated overnight for 18 -
221 24 hours at 37°C . Colony material of pure cultures was transferred by direct smearing onto
222 spots of the MALDI-TOF MS target with tooth-picks. Bacterial identification was reported to
223 the species level if the score value was above 2.00 or to the genus level if the score was between
224 1.70 and 1.99. A minority of isolates that could not be successfully identified by MALDI-TOF
225 MS were identified by sequencing of the 16S rRNA gene. For this purpose, a 1465p fragment
226 of the 16S rRNA gene was amplified by PCR using primers 27F and 1492R (Weisburg et al.,
227 1991). Thermocycling conditions were as follows: 5 min at 95°C , followed by 35 cycles of 45
228 s at 95°C , 1 s at 55°C and 1:30 min at 72°C , and a final extension step at 72°C for 10 min.
229 Amplicons were sent to Macrogen (Amsterdam, Netherlands) for Sanger sequencing in the
230 forward direction. The resulting sequences were characterised using BLASTn
231 (<http://www.ncbi.nlm.nih.gov/BLAST/>). All sequences were identified to species level ($\geq 99\%$
232 sequence identity).

233 **2.5. Antibiotic susceptibility testing**

234 All isolates were subjected to antibiotic susceptibility testing using the disk diffusion
235 method (EUCAST, 2020). The antibiotics used were amoxicillin (AML, 25 µg),
236 amoxicillin/clavulanic acid (AMC, 30 µg), cephalexin (CL, 30 µg), cefuroxime (CXM, 30 µg),
237 ceftazidime (CAZ, 10 µg), cefepime (FEP, 30 µg), ertapenem (ETP, 10 µg), imipenem (IPM,
238 10 µg), meropenem (MEM, 10 µg), gentamicin (GM, 10 µg), trimethoprim/sulfamethoxazole
239 (SXT, 1.25/23.75 µg) and ciprofloxacin (CIP, 5 µg). The AML, CL and CAZ disks were
240 purchased from Oxoid, and the others from BD (BBL, USA). Isolates that were resistant to any
241 of the carbapenems underwent minimum inhibitory concentration (MIC) determination by
242 serial broth microdilution according to EUCAST (2020) guidelines. In addition, colistin (COL)
243 resistance of all isolates was determined by MIC. Briefly, in a sterile 96-well plate, a starting
244 concentration of 64 mg/L (COL, IPM, and MEM) or 16 mg/L (ETP) was used and serially
245 diluted twofold to a final concentration of 1 mg/L (COL, IPM, and MEM) or 0.25 mg/L (ETP).
246 The remaining two columns were used as a positive control for bacterial growth (no antibiotic)
247 and a negative control (no bacteria added). The wells contained 90 µl of Mueller-Hinton broth
248 (Merck, Germany) or cation adjusted Mueller-Hinton broth 2 (Sigma-Aldrich, Germany; in the
249 case of COL) and serially diluted target antibiotics. Overnight bacterial cultures were diluted to
250 a concentration of 5×10^5 CFU/mL, and each well was inoculated with 10 µl of the culture. The
251 plates were incubated overnight at 37° C, and the lowest concentration at which no visible
252 growth was observed was determined as the MIC of the sample. Strains *Escherichia coli* ATCC
253 25922 and *Escherichia coli* NCTC 13846 were used as quality controls. The isolates were
254 classified as multidrug-resistant (MDR), extensively drug-resistant (XDR), or pandrug-resistant
255 (PDR) according to the definitions of Magiorakos et al. (2012). Finally, isolates were clustered
256 into groups according to the similarity of their resistance patterns, and representatives of each
257 group were used for further targeted PCRs.

258 **2.6. Phenotypic identification of ESBLs, pAmpC and carbapenemases**

259 For the detection of ESBL production, CTX-R isolates underwent the double disc synergy
260 test according to EUCAST guidelines ([http://www.amcli.it/wp-](http://www.amcli.it/wp-content/uploads/2015/10/EUCAST_detection_resistance_mechanisms_V1.pdf)
261 [content/uploads/2015/10/EUCAST_detection_resistance_mechanisms_V1.pdf](http://www.amcli.it/wp-content/uploads/2015/10/EUCAST_detection_resistance_mechanisms_V1.pdf)). Briefly,
262 overnight cultures of isolates were diluted in saline to 0.5 McFarland concentration and plated
263 on Mueller-Hinton agar plates with a sterile cotton swab. Paired CAZ (30 µg) and CTX (30 µg)
264 discs were used, which were 20 mm and 30 mm (centre to centre) from the amoxicillin-
265 clavulanate disc (AMC, 20+10 µg), respectively. Plates were incubated overnight at 37°C. An
266 increase in the zone of inhibition (synergy with clavulanate) for one of the extended-spectrum
267 cephalosporins was considered a positive result for ESBL production.

268 To screen for pAmpC production, CTX-R isolates were subjected to a combined disk
269 test using phenylboronic acid (Gupta et al., 2014). Briefly, the cefoxitin disk (30 µg) alone and
270 in combination with phenylboronic acid (300 µg) were placed on the inoculated Mueller-Hinton
271 agar plates. After overnight incubation at 37° C, an increase in the zone of inhibition of ≥5 mm
272 indicated pAmpC production.

273 To detect carbapenemase production, CR isolates were subjected to the in-house Carba
274 NP test (Nordmann et al., 2012). Briefly, bacterial suspensions in Tris-HCL lysis buffer were
275 mixed with 100 µL phenol red solution containing ZnSO₄ x 7H₂O (0.1 mM) and imipenem-
276 cilastatin (12 mg/mL). After incubation at 37°C for a maximum of 2 hours, the bacterial strains
277 that changed the color of the suspension from red to orange or yellow were considered to be
278 carbapenemase producers.

279 **2.7. Targeted PCRs**

280 Targeted PCRs were performed on a subset of isolates with different AR profiles. Total
281 bacterial DNA was extracted from bacterial overnight cultures using the Quick-DNA™
282 Miniprep Plus Kit (Zymo, USA) according to the manufacturer's instructions. Isolates with
283 confirmed ESBL production were tested for the presence of ESBL genes by multiplex PCR

284 (*bla*_{TEM}, *bla*_{SHV}, *bla*_{PER}, *bla*_{VEB}, *bla*_{GES} and *bla*_{SME}) and singleplex PCR (*bla*_{CTX-M} groups 1, 2,
285 and 9). In addition, these isolates underwent multiplex PCR for pAmpC genes (*bla*_{MOX}, *bla*_{CIT},
286 *bla*_{DHA}, *bla*_{ACC}, *bla*_{EBC}, and *bla*_{FOX}). All isolates with confirmed CP production underwent PCR
287 for the following CP genes: *bla*_{IMP}, *bla*_{KPC}, *bla*_{NDM}, *bla*_{OXA-48}, and *bla*_{VIM}. Bacterial isolates that
288 were identified as colistin-resistant in broth microdilution assays underwent multiplex PCR for
289 the following genes: *mcr*-1, *mcr*-2, *mcr*-3, *mcr*-4 and *mcr*-5. Primer sequences and
290 thermocycling conditions are listed in Table S3. All positive PCR products were purified using
291 NucleoSpin Gel and PCR Clean-up (Macherey-Nagel, Germany) and underwent Sanger
292 sequencing in the forward direction (Macrogen). Resulting sequences were edited and
293 compared with reference sequences in the NCBI database using the online BLASTX search.

294

295 **2.8. Genotyping by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing** 296 **(MLST)**

297 Isolates of *E. coli*, *Klebsiella* spp., and *Enterobacter* spp. were subjected to genetic
298 relatedness determination by PFGE of *Xba*I-digested genomic DNA using the CHEF-DR III
299 system (Bio-Rad Laboratories, USA), as previously described (Jelic et al., 2016). Restriction
300 patterns were analysed with BioNumerics software (Applied Maths, Belgium) using the DICE
301 coefficient (tolerance 1.5%), and the dendrogram was generated with UPGMA. Isolates that
302 had a similarity cut-off of ≥ 85 % of their banding patterns were assigned to the same cluster.

303 One representative of each cluster was analysed for the presence of a sequence type (ST)
304 using the commercial service IDgenomics (Seattle, USA) or by whole genome sequencing
305 (WGS, see below). In the case of the commercial service, the sequences of 7 housekeeping
306 genes of 3 *E. coli* and 1 *K. pneumoniae* were typed using the database <https://pubmlst.org/>.

307

308 **2.9. Whole genome sequencing (WGS) and sequence analysis**

309 Based on the results of antibiotic susceptibility testing and their clinical significance,
310 selected isolates of *E. coli*, *K. pneumoniae*, and *E. cloacae* complex (cplx) were subjected to
311 WGS, resulting in the sequencing of 4 *E. coli*, 2 *K. pneumoniae*, 2 *Enterobacter asburiae*, 3
312 *Enterobacter cloacae*, 1 *Enterobacter ludwigii* and 1 *Enterobacter kobeii*. DNA was extracted
313 from frozen isolates revived by two consecutive smears on LB agar plates with CTX or IPM (4
314 mg/L) and subculture overnight in LB broth with the appropriate antibiotic (4 mg/L CTX or
315 IPM). Sequencing was performed on the Ion Torrent PGM platform (Life Technologies, USA)
316 according to the manufacturer's instructions. The Ion Xpress Plus Fragment Library Kit was
317 used to enzymatically shear 100 ng of genomic DNA. The target fragment size was 400 bp.
318 Subsequently, the fragmented DNA was processed using the Ion DNA Barcoding Kit (Life
319 Technologies, USA) and its size was selected using the E-Gel SizeSelect 2 % Agarose Kit (Life
320 Technologies, USA). The size and distribution of DNA fragments were analysed using the High
321 Sensitivity Kit (Agilent, USA). Further sample preparation was performed using the Ion
322 OneTouch Kit (Life Technologies, USA). Finally, the amplified DNA was sequenced using the
323 318 Chip (Life Technologies, USA). The raw data were assembled *de novo* using the Assembler
324 SPAdes software, ver. 3.1.0., which is part of the Assembler plugin on the Ion Torrent server.
325 Genomes were annotated using the Rapid Annotation using Subsystem Technology (RAST)
326 database (Aziz et al., 2008; Overbeek et al., 2014). ARGs were found using ResFinder
327 (Bortolaia et al., 2020). STs and plasmid replicon types were identified using tools from the
328 Center for Genomic Epidemiology website (Larsen et al., 2012; Carratoli et al., 2014).

329 Screening for chromosomal mutations in genes associated with colistin resistance was
330 performed using the reference genome of *E. cloacae* ATCC 13047 (NCBI GenBank Accession
331 No. CP001918). *E. cloacae* ATCC 13047 was screened for reference amino acid sequences of
332 PmrA, PmrB, PhoP, PhoQ, and MgrB. Whole genome sequences of 6 *Enterobacter* spp. isolates
333 were used to search for chromosomal mutations causing resistance to colistin in *Enterobacter*

334 spp. by sequence BLASTing (<http://blast.ncbi.nlm.nih.gov>). The effect of mutation as
335 neutral/detrimental was determined using the freely available PROVEAN (Protein Variation
336 Effect Analyzer) v1.1.3 software (http://provean.jcvi.org/seq_submit.php).

337

338 **2.10. Data analysis**

339 Bacterial and gene concentration data were first log₁₀-transformed before further
340 analysis. The unpaired Welch's t-test was used to compare the average concentration of target
341 organisms (total coliforms, *E. coli*, other coliforms) in hospital wastewater and the absolute
342 concentration of EOPs between seasons. In addition, the relative abundance of ESBL and CP
343 genes between seasons in each hospital wastewater was assessed using a multiple unpaired t-
344 test. All statistical analyses and data visualisations were performed using GraphPad Prism ver.
345 9.4.0 for Windows (GraphPad Software, San Diego, California, USA).

346

347

348 **2.11. Data accessibility**

349 The submission of Sanger sequence data to GeneBank is underway. Whole genome
350 sequencing data have been submitted under BioProject: PRJNA913323 with BioSample
351 accession numbers SAMN32292703 - SAMN32292715.

352

353 **3. Results**

354 **3.1. Concentrations of total, CTX-R and CR *E. coli* and other coliforms**

355 Cultivation on non-selective and two different selective plates revealed the presence of
356 total and presumptive CTX-R *E. coli* and non-*E. coli* coliforms (Biorad Rapid'*E. coli* 2 agar
357 plates with CTX) and presumptive CR *E. coli* and non-*E. coli* coliforms (CHROMagar
358 mSuperCARBA plates) in all hospital wastewater samples (Fig. 1). The average concentration

359 of total *E. coli* and non-*E. coli* coliforms in wastewater from the two hospitals was 9×10^3 and
360 2.5×10^4 CFU/mL, respectively. In comparison, significantly lower concentrations of
361 presumptive CTX-R *E. coli* (4.8×10^2 CFU/mL) and non-*E. coli* (6.8×10^3 CFU/mL) were
362 measured. However, the concentrations of presumptive CR *E. coli* and non-*E. coli* coliforms in
363 the analysed wastewater samples were slightly higher than the corresponding CTX-R
364 concentrations and were consistent with the total concentrations of the corresponding species
365 (Fig. 1, Table S4). No significant seasonal changes were detected in presumptive CTX-R or CR
366 *E. coli* and non-*E. coli* coliforms.

367 368 **3.2. Abundance of ESBL and CP genes in hospital wastewater**

369 Two ESBL (*bla*_{TEM}, *bla*_{CTX-M-32}) and five CP genes (*bla*_{KPC-3}, *bla*_{OXA-48-like}, *bla*_{NDM}, *bla*_{IMP},
370 *bla*_{VIM}) were detected in all hospital wastewater samples using qPCR (Fig. 2). The
371 concentrations of *bla*_{TEM} and *bla*_{CTX-M-32} were mostly between approx. 10^{-3} and 10^{-4} gene
372 copies/*rrn* copies (Fig. 2A). Regarding seasonal variations, hospital H1 had significantly higher
373 levels of *bla*_{TEM} in summer samples, whereas hospital H2 had significantly higher levels of
374 *bla*_{CTX-M-32} in the same season (unpaired t-test, $p < 0.01$). Among the CP genes, *bla*_{KPC-3} was the
375 most abundant in wastewater of both hospitals, with significantly higher levels in summer
376 (approx. 10^{-1} gene copies/*rrn* copies) compared to winter samples (approx. 10^{-3} gene copies/*rrn*
377 copies) (unpaired t-test, $p < 0.01$; $p < 0.001$) (Fig. 2B). The relative abundance of the other CP
378 genes examined mostly ranged from approx. 10^{-3} to 10^{-4} gene copies/*rrn* copies with no
379 significant seasonal differences observed, except for *bla*_{VIM} in H1 and *bla*_{OXA-48} in H2 with
380 significantly higher levels in summer samples. The colistin resistance gene *mcr-1* was not found
381 in any of the hospital wastewater.

382 383 **3.3. Concentrations of total bacteria and EOPs in hospital wastewater**

384 The qPCR-based analyses of the bacterial *rrn* gene showed that the mean concentration of
385 total bacteria in the winter wastewater samples was approx. 10^8 CE/mL and was significantly
386 lower in the summer samples (10^7 CE/mL) (Welch's t-test, $p < 0.001$) (Fig. 3). In addition,
387 quantification of specific taxonomic markers for EOPs such as *E. coli* (*yccT*), *K. pneumoniae*
388 (*gltA*), *A. baumannii* (*secE*), and *Enterococcus* spp. (23S rRNA) showed that there were no
389 significant differences in gene abundances between seasons, although median levels for *A.*
390 *baumannii* were considerably higher in summer than in winter samples. In general, *E. coli* was
391 the most abundant species in the hospital wastewater samples (approx. 10^5 CE/mL), whereas
392 the concentrations of the other EOPs were approx. 10^4 CE/mL, with the exception of *A.*
393 *baumannii* in summer.

394

395 **3.4. Identification of isolates**

396 A total of 200 presumptive enterobacteria were successfully isolated on selective media
397 supplemented with antibiotics (CTX or carbapenems) from wastewater samples from both
398 hospitals. Of these, we identified 159 members of the order *Enterobacterales* and 41 strains not
399 belonging to this order by MALDI-TOF or 16S rRNA gene sequencing (Fig. S1A).
400 *Enterobacterales* isolates included 69 CTX-R (27 from H1 and 42 from H2) and 90 CR isolates
401 (43 from H1 and 47 from H2) (Fig. S1B). The identified *Enterobacterales* from both hospitals
402 belonged to eight different genera, namely *Escherichia* (n=58), *Citrobacter* (n=39),
403 *Enterobacter* (n=29), *Klebsiella* (n=23), *Raoultella* (n=5), *Kluyvera* (n=3), *Morganella* (n=1),
404 and *Serratia* (n=1) (Fig. S1C).

405

406 **3.5. Phenotypic tests for detection of β -lactamases**

407 All presumptive CTX-R *Enterobacterales* isolates (n=69) were found to be positive for
408 ESBL production in the double disk synergy test. Of these, 35 % of isolates (n=24) were also

409 phenotypically positive for pAmpC production in the phenylboronic acid disk test, and 32 %
410 (n=20) were positive for CP production in the Carba NP test. In addition, all presumptive CR
411 *Enterobacterales* isolates (n= 90) were confirmed as CPE by the Carba NP test.

412

413 **3.6. Antibiotic susceptibility patterns**

414 All 159 *Enterobacterales* isolates from hospital wastewater (both ESBL-E and CPE) were
415 tested for antibiotic susceptibility by the agar disk diffusion and broth microdilution methods
416 (Fig. 4). Of the β -lactam antibiotics tested, all isolates were resistant to penicillins (AML,
417 AMC), 1st (CL) and 2nd generation cephalosporins (CXM). More than 85% of ESBL-E and >
418 95% of CPE isolates were resistant to 3rd (CAZ) and 4th generation cephalosporins (FEP),
419 respectively. Almost all CPE isolates showed resistance to all three carbapenems tested,
420 whereas half of the ESBL-E isolates were found to be carbapenem-resistant (51%, ETP).
421 Regarding resistance to other classes of antibiotics, high rates of resistance to fluoroquinolones
422 (CIP; $\geq 87\%$) were observed in both groups of isolates. Resistance to aminoglycosides (GM)
423 occurred more frequently in ESBL-E (75%) than in CPE isolates (57%). Trimethoprim-
424 sulfonamide resistance (SXT) was confirmed in 36% of isolates in both groups. Colistin
425 resistance was found at relatively low levels, but in a higher percentage (27%) in CPE than in
426 ESBL-E isolates (9%).

427 Intrinsic resistance was considered in the evaluation of multidrug-resistant (MDR) and
428 extensively drug-resistant (XDR) profiles of *Enterobacterales* isolates (Magiorakos et al.,
429 2012). MDR was found in all isolates (ESBL-E and CPE), and approximately 50 % of ESBL-
430 E and 80 % of CPE isolates were XDR (Fig. 4). In addition, one CPE isolate (*E. kobei*) was
431 classified as pan-drug resistant (PDR), because it was resistant to all antibiotics tested.

432

433 **3.7. Molecular detection of ARGs**

434 The subset of 42 ESBL-E isolates underwent targeted PCR to detect ESBL and pAmpC
435 genes. Of these isolates, those identified as colistin- or carbapenem-resistant underwent a PCR-
436 based analysis targeting plasmid-mediated colistin resistance genes or CP genes, respectively.
437 Sanger sequencing of the amplicons was used to determine the gene variant (Table 1). The most
438 frequently detected ESBL gene was *bla*_{CTX-M-1} group genes, specifically *bla*_{CTX-M-15}, which was
439 present in 30 isolates, mainly *E. coli* (n=13) and *K. pneumoniae* (n=8), while *bla*_{CTX-M-3} was
440 detected in 4 isolates (Table 1). This was followed by *bla*_{TEM-116}, which was detected in 22 ESBL
441 isolates. Other ESBL genes detected were *bla*_{SHV} (*bla*_{SHV-12} and *bla*_{SHV-28}) and *bla*_{GES-7}, which
442 were detected only in *Klebsiella* spp. Nineteen ESBL-E isolates possessed two ESBL genes,
443 mainly *bla*_{CTX-M-15+TEM-116} (Table 1). Additionally, 12/42 isolates possessed CP genes, mainly
444 *bla*_{KPC-2} (n=6) and *bla*_{OXA-48} (n=5), whereas *bla*_{NDM-1} was detected in only one isolate (*K.*
445 *oxytoca*) (Table 1). The latter *K. oxytoca* was the only isolate in which 5 β-lactamase genes
446 were detected (*bla*_{CTX-M-15}, *bla*_{TEM-1}, *bla*_{GES-7}, *bla*_{EBC} and *bla*_{NDM-1}) (Table 1). In addition, the
447 pAmpC multiplex PCR revealed the presence of *bla*_{EBC} (6/42 isolates, mainly in *E. cloacae*
448 complex (cplx) and *Klebsiella* spp.), *bla*_{CIT} (6/42, found only in *Citrobacter* spp.), and *bla*_{MOX}
449 genes (4/42, found only in *E. coli*).

450 Of the 43 CPE isolates selected for targeted PCR, CP genes were detected in almost all
451 isolates (41/43). The *bla*_{KPC-2} (20/43, 47%) and *bla*_{NDM-1} (19/43, 44 %) genes were the two most
452 frequently detected ones, especially in *Citrobacter* spp. (Table 2). *E. cloacae* cplx strains (n=5)
453 and *E. coli* (n=4) were also frequent carriers of *bla*_{KPC-2}, whereas *K. pneumoniae* was a frequent
454 carrier of *bla*_{NDM-1} (n=7).

455 Other CP genes detected were *bla*_{OXA-48} (15/43 isolates, 35%, mostly in *K. pneumoniae*) and
456 *bla*_{VIM-1} (9/43, 21%, mostly in *E. cloacae* cplx and *Citrobacter* spp.) (Table 2), whereas the
457 17/43 CPE isolates had two or more CP genes. Among these 17 isolates, the most frequent
458 combination of genes was *bla*_{OXA-48+NDM-1} in *K. pneumoniae* (n=5) and *Citrobacter* spp. (n=1)

459 and *bla*_{KPC-2+NDM-1} in *E. cloacae* cplx (n=2) and *Citrobacter* spp. (n=3) (Table 2). The most
460 common combination of three CP genes were *bla*_{KPC-2+NDM-1+VIM-1}, detected in *Citrobacter* spp
461 (n=3).

462 Both ESBL-E and CPE isolates were negative for mobile colistin resistance genes
463 (*mcr1-mcr5*).

464 **3.8. Molecular epidemiology of *E. coli*, *K. pneumoniae* and *E. cloacae* cplx isolates**

466 Clonal relatedness of all (ESBL-E and CPE) *E. coli* (n=58), *K. pneumoniae* (n=22) and
467 *E. cloacae* cplx isolates (n=26) was determined by PFGE, and ST was determined for one
468 representative isolate from each cluster.

469 For *E. coli*, a total of 6 PFGE clusters were found: A (n=2), B (n=4), C (n=7), D (n=8),
470 E (n=15), F (n=2); 14 isolates could not be assigned to any cluster and 5 could not be typed.
471 Five different STs were found among the clustered isolates: ST216, ST405, ST361, ST541, and
472 ST131. Isolates from clusters D and F had the same ST131, while the ST of the largest cluster
473 (E) could not be determined. The distribution of *E. coli* isolates among clusters showed
474 partitioning between hospitals. The largest cluster (E) included 15 isolates (with *bla*_{KPC-2} or
475 *bla*_{TEM-1/TEM-116+bla}_{CTX-M-15+bla}_{MOX+bla}_{KPC-2}), all of which were from H2 hospital wastewater.
476 Most of them showed the same AR profile and were sensitive only to SXT and COL. The *E.*
477 *coli* strains of another dominant cluster (D) were ST type ST131 (*bla*_{TEM-1} or *bla*_{TEM116+bla}_{CTXM-}
478 ₁₅), and all but one were from H2. The isolates of the third dominant cluster (C) belonged to
479 ST541 (*bla*_{KPC-2}), were all derived from H1. They were only sensitive to GM, SXT and COL.
480 Isolates from the latter two clusters (C and D) had phenotypic resistance to a lower number of
481 antibiotics tested than those from the largest cluster E.

482 Among the 22 *K. pneumoniae* isolates, 3 PFGE clusters were found among 13 isolates,
483 whereas the remaining 9 isolates were singletons (Fig. 5B). Three different ST were identified:
484 ST16, ST101, and ST307. The largest cluster B included 9 isolates from H2 wastewater

485 belonging to ST101, and most of them showed resistance to all antibiotics tested, except
486 colistin, and carried *bla*_{OXA-48} or *bla*_{OXA-48}+*bla*_{NDM-1}.

487 For the *E. cloacae* cplx, PFGE genotyping was assessed per species (Fig. 5C). The *E.*
488 *cloacae* (n=16) were grouped into 3 clusters (n=11), and the remaining 5 isolates were
489 singletons. Cluster C was the largest and included 6 isolates from H2 wastewater that were ST
490 type ST277 and showed phenotypic resistance to carbapenems (*bla*_{KPC-2}) and colistin but were
491 sensitive to GM and SXT (Fig. 5C). The ST type of the second largest cluster (B) could not be
492 determined (*bla*_{VIM-1}), whereas 2 isolates of cluster A belonged to ST32. Of the *E. asburiae*
493 isolates (n=7), only 4 were in a cluster (cluster A), originated from H2 and belonged to ST277
494 (*bla*_{KPC-2}+*bla*_{NDM-1}). The remaining 3 isolates were singletons (Fig. 5C). Three *E. ludwigii*
495 isolates from H2 wastewater had a similarity percentage >94%, and belonged to ST277. These
496 isolates had the same genotypic (*bla*_{KPC-2}) and phenotypic resistance profile as *E. cloacae*
497 isolates from cluster C (Fig. 5C). Two *E. bugadensis* isolates were singletons, and one *E. kobei*
498 was not included in this analysis.

499

500 **3.9. Presence of ARGs, STs and plasmid replicon types in isolates by WGS analysis**

501 A total of 13 isolates were subjected to WGS analysis - four *E. coli*, two *K. pneumoniae*,
502 three *E. cloacae*, two *E. asburiae*, one *E. ludwigii*, and one *E. kobei* (Table S8). This selection
503 mainly included isolates from dominant and distinct clusters with clinically-relevant features,
504 such as resistance to carbapenems and/or colistin.

505 Of the four different *E. coli* isolates, the STs were identified for three of them, including
506 ST361, ST131, and ST541 while one isolate could not be typed. All three ESBL-producing *E.*
507 *coli* (ST361, ST131 and ND) contained *bla*_{CTX-M} genes (*bla*_{CTX-M-15} and/or *bla*_{CTX-M-194}) and the
508 *bla*_{OXA-1} gene, whereas one ST361 strain additionally possessed *bla*_{TEM-1B}. In addition, all *E.*
509 *coli* isolates contained the pAmpC *bla*_{EBC} gene. Phenotypic resistance to aminoglycosides was

510 supported by the detection of *acc(6')-Ib-cr* and/or *aac(3)-IIa* genes, whereas resistance to
511 fluoroquinolones was supported by the presence of *qnrB1* and/or *acc(6')-Ib-cr*, to
512 chloramphenicol by the detection of *catB3* and to trimethoprim/sulfamethoxazole by *dfrA12*
513 gene. Other resistance genes found comprised the *lnuF* gene (lincomycin resistance), *tetA*
514 (tetracycline resistance), and *sitABCD* gene (resistance to biocides - hydrogen peroxide). Two
515 ESBL-producing *E. coli* isolates (ST361 and ND) were phenotypically identified as
516 carbapenem resistant, but WGS analysis did not detect carbapenem resistance genes in them,
517 whereas the presence of *bla_{KPC-2}* was detected by PCR in one of them. This gene was also
518 detected in CP-producing *E. coli* (ST541), and phenotypic resistance to fluoroquinolones was
519 confirmed by the detection of the *qnrS1* gene.

520 Two CP-producing *K. pneumoniae* isolates belonged to ST16 and ST101, respectively
521 (Table S8). According to WGS, these two isolates carried the *bla_{OXA-48}* gene; however, targeted
522 PCR additionally detected the presence of *bla_{NDM-1}*. They also possessed ESBL genes such as
523 *bla_{CTXM-15}*, *bla_{SHV-205}*, and *bla_{OXA-1}*. Additional genes responsible for resistance to
524 trimethoprim/sulfamethoxazole (*dfrA14*), (fluoro)quinolones (*aac(6')-Ib-cr*, *oqxA*, *oqxB*,
525 *qnrB1*), fosfomycin (*fosA*, *fosA5*), or chloramphenicol (*catB3*) were also detected in these
526 isolates.

527 *E. cloacae* cplx included ST277 isolates (2 *E. asburiae*, *E. cloacae*, and *E. ludwigii*),
528 ST32 (*E. cloacae*) and ST501 (*E. kobei*), whereas one isolate could not be assigned into any
529 ST. Carbapenemase production activity was supported by the WGS-based detection of *bla_{KPC-}*
530 *2* in ST277 and ST501 isolates or *bla_{VIM-1}* genes (unknown ST), and targeted PCR additionally
531 detected *bla_{NDM-1}* in two *Enterobacter* isolates (ST277, ST501). In addition to the *bla_{TEM}* gene,
532 which was detected in all but one *Enterobacter* spp., other resistance genes for β -lactams were
533 observed, including *bla_{CTX-M-3}* (in ST501), *bla_{OXA-1}* (in ST277), *bla_{OXA-10}* (in ST277, ST32),
534 and *bla_{OXA-14}* (in ST501). Each isolate contained one *bla_{ACT}*/*bla_{MIR}* gene. Three isolates with

535 phenotypic gentamicin resistance contained *aac(6')-Ib-cr*, *aac(3)-I*, *aph(3'')-Ib*, and *aph(6')-Id*
536 genes, and four gentamicin-susceptible isolates contained *aac(3')-I* and *aadA11* or *aac(6')-Ib-*
537 *cr*. Of the 7 isolates displaying phenotypic ciprofloxacin resistance, two contained *qnrB1* or
538 *qnrS1* genes and no ciprofloxacin resistance genes were detected in the five isolates. Two
539 *Enterobacter* isolates with phenotypic trimethoprim/sulfamethoxazole resistance contained the
540 *sul1*, *sul2* and *dfrA14* genes. Other genes responsible for resistance to fosfomycin (*fosA*),
541 rifampicin (*arr-3*), chloramphenicol (*catB3*), and the biocides (*qacE*) were also found
542 sporadically. No plasmid-mediated *mcr* colistin resistance genes were detected in ST277, ST32
543 and ST501 strains that were phenotypically resistant to colistin. These isolates had mutations
544 in three or more genes (*pmrA*, *pmrB*, *phoP*, *phoQ* and *mgrB*) which are associated with colistin
545 resistance. The total number of numerous mutations detected in all six *Enterobacter* spp.
546 isolates was 343 and the analysis in PROVEAN revealed 91 unique mutations (6 deleterious -
547 PmrA – P174A; PmrB – E218G, S308Q, G309R, L310S; PhoP – N174S; and 85 neutral
548 mutations) (Table S9). Multiple amino acid substitutions were noted for all proteins except for
549 MgrB that had one amino acid substitution (V10I) found in 4 *Enterobacter* spp. isolates. The
550 L133I mutation in the *phoQ* gene was reported for the first time in this study, as indicated in
551 Table S9.

552 The genetic context of the *bla_{CTX-M}*, *bla_{OXA-48}*, *bla_{KPC-2}*, and *bla_{VIM-1}* genes was analysed
553 using RAST annotations (Fig. 6). The *bla_{CTX-M}* genes (*bla_{CTX-M-15}*, *bla_{CTX-M-194}* and *bla_{CTX-M-3}*)
554 were flanked by insertion sequences (*ISEc9* or IS6 family) and/or transposases (Tn3 family) in
555 all genomes (analysed by WGS) in which these genes were detected (6/13). The *bla_{OXA-48}* gene
556 was flanked by a *lysR* gene in *K. pneumoniae* ST101 and ST16 and by an IS4 family insertion
557 sequence in *K. pneumoniae* ST101. The *bla_{KPC-2}* gene was flanked in five *Enterobacter* spp.
558 (ST277 and ST501) by genes belonging to the Tn3-based transposon family (*ISKpn6* and
559 *ISKpn27*). Two ST277 *Enterobacter* isolates (*E. cloacae* and *E. ludwigii*) carried *bla_{KPC-2}*

560 together with the *bla*_{TEM-1} gene as part of this Tn3 transposon. Similarly, *bla*_{KPC-2} was present in
561 ST541 *E. coli* associated with the Tn3-based transposon, Tn4401. The *bla*_{VIM-1} was associated
562 in *E. cloacae* (unknown ST) with genes encoding resistance to aminoglycosides (*aac(6')-Ib-cr*,
563 *aadA1*), biocides (*qacEΔ1*), and sulfonamides (*sul1*).

564 Finally, plasmids were detected in all 13 sequenced isolates, with eleven isolates
565 containing more than one replicon (Table S8). In total, 19 different plasmid replicon types were
566 identified in *E. coli*, *K.pneumoniae*, and *Enterobacter* spp. The most frequently detected
567 plasmid replicon types were IncFIB (n=9) and IncHI2 (n=6).

568

569 **4. Discussion**

570 This study focused on the resistance to 3rd generation cephalosporins and carbapenems,
571 especially among *Enterobacteriales*, which are now among the most prevalent ARB threatening
572 human health. Monitoring of these bacteria and their ARGs from high-risk point sources such
573 as hospital wastewater is critical to obtain the information needed to track their spread in the
574 environment.

575 The culture-based enumeration of *E. coli* and other coliforms resistant to CTX (3rd
576 generation cephalosporin) or carbapenems in hospital wastewater analysed here showed that
577 concentrations ranged from 10³ to 10⁴ CFU/mL, which is up to two orders of magnitude higher
578 than in the influent of the receiving WWTP in Zagreb (Puljko et al, 2022). This high prevalence
579 of CTX-R and CR *E. coli* and non-*E.coli* coliforms in wastewater from the two large hospitals
580 in Zagreb is comparable or lower than in several previous studies, including hospital wastewater
581 from neighbouring Austria and Slovenia (Rozman et al, 2020). The lack of on-site treatment of
582 sewage in Zagreb hospitals exacerbates the potential for further spread and resulting health
583 impact of bacterial resistance to last-line antibiotics such as carbapenems.

584 The further quantification of five CP genes (*bla*_{OXA-48}, *bla*_{KPC-3}, *bla*_{NDM}, *bla*_{IMP}, and
585 *bla*_{VIM}) by qPCR in wastewater from both hospitals showed that *bla*_{KPC-3} was detected at the
586 highest levels and reached relative levels of up to 10⁻¹ gene copies/*rrn* copies. These levels were
587 unusually high compared to previously published concentrations of *bla*_{KPC} in hospital
588 wastewater samples (around 10⁻⁵ gene copies/*rrn* copies) (Zhang et al, 2020). This high
589 prevalence of *bla*_{KPC} in the studied hospital wastewater is consistent with the frequent detection
590 of KPC-producing isolates in Croatian hospitals, especially *K. pneumoniae* (Bedenić et al, 2015,
591 2021; Jelić et al, 2016). The potential risk of this gene would be exacerbated by the possibility
592 of horizontal transmission between strains, as has already been demonstrated in clinical isolates
593 in Croatia (Jelić et al, 2016). Finally, the fact that *bla*_{KPC} is predominantly associated with
594 hospital wastewater but rarely detected in the environment (Jelić et al., 2019; Hooban et al.,
595 2020) may lead to the prioritisation of monitoring this gene to detect potential leakage from
596 inadequately treated hospital wastewater. The concentrations of other CP genes, *bla*_{OXA-48},
597 *bla*_{NDM}, *bla*_{VIM}, and *bla*_{IMP}, as well as two ESBL genes, *bla*_{TEM} and *bla*_{CTX-M-32}, were within the
598 range of previous studies (~10⁻³ to 10⁻⁴ gene copies/*rrn* copies) (Rodriguez-Mozaz et al., 2015;
599 Flach et al., 2021). Moreover, the qPCR-based quantification of the WHO priority pathogens
600 *E. coli*, *K. pneumoniae*, *A. baumannii*, and *Enterococcus* spp. showed that hospital wastewater
601 contained all of these pathogens at concentrations of 10³ to 10⁵ CE/mL (or 10⁻³ to 10⁻⁵ CE/*rrn*
602 copies), which were comparable to those measured in German hospital wastewater samples
603 (Alexander et al 2022). All these results confirm that hospital waste is an important reservoir
604 for high-priority pathogens and ARGs and a pathway for their dissemination in water systems.

605 To place the obtained ARG data in a medical context, culture-based methods paired
606 with molecular methods such as WGS and PCR were used to investigate the phenotypic and
607 molecular mechanisms of resistance in CR and CTX-R enterobacterial isolates. Sixty-nine
608 CTX-R and 90 CR *Enterobacterales* were successfully isolated from our hospital wastewater

609 samples. The mechanisms underlying resistance to CTX and carbapenems in these isolates were
610 the production of ESBL and carbapenemases, respectively. Among the CPE isolates,
611 *Citrobacter* spp. (34 %), *Enterobacter* spp. (26 %), *E. coli* (18 %) and *Klebsiella* spp. (16 %),
612 dominated, whereas *E. coli* (61 %), *Klebsiella* spp. (13 %), and *Citrobacter* spp. (12 %) were
613 predominant among ESBL-E isolates. All isolates tested were found to be MDR, consistent
614 with the ability of enterobacteria to acquire various ARGs via HGT, which is mostly mediated
615 by plasmids (Cantón et al., 2012)

616 ESBL-E isolates had high rates of resistance to fluoroquinolones (87 %),
617 aminoglycosides (75 %), and even carbapenems (ETP, 51%), in addition to 3rd and 4th
618 generation cephalosporins. Further genetic characterization of these isolates revealed that the
619 most common ESBL genotype was *bla*_{CTX-M-15} (71 %) and *bla*_{TEM-116} (52 %), whereas *bla*_{SHV}
620 (12 %) (*bla*_{SHV-12} and *bla*_{SHV-28}) was rare. Moreover, *bla*_{CTX-M-15} and *bla*_{TEM-116/TEM-1} co-occurred
621 in the majority of our *E. coli*, *Klebsiella* spp. and *Citrobacter* spp. isolates, whereas *bla*_{CTX-M-}
622 ₁₅, *bla*_{TEM}, and *bla*_{SHV} co-occurred only in *K. pneumoniae* isolates (10 %). This is consistent
623 with previous reports from Zagreb hospitals, including H1 studied here, describing a frequent
624 association of these genes in clinical enterobacterial isolates (Bedenić et al., 2016; D’Onofrio
625 et al., 2020). In addition, co-production of ESBL (*bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV}), pAmpC (*bla*_{MOX},
626 *bla*_{EBC} or *bla*_{CIT}), and CP genes (*bla*_{KPC-2}, *bla*_{OXA-48} or *bla*_{NDM-1}) was observed in some of the
627 ESBL-E isolates analysed here, consistent with a worldwide survey of clinical enterobacterial
628 isolates (Kazmierczak et al., 2021).

629 CPE isolates showed a high rate of resistance to all β -lactam antibiotics tested,
630 including carbapenems, and to fluoroquinolones (99 %), but also to a lesser extent to
631 aminoglycosides (57 %). However, 27 % CPE isolates were resistant to colistin, which may
632 lead to treatment failure if spread further, as carbapenems and colistin are considered as last
633 choice antibiotics for the treatment of MDR bacteria. The *bla*_{KPC-2} and *bla*_{NDM-1} were the most

634 frequently detected CP genes in this study, particularly in *Citrobacter* spp. These species are
635 becoming increasingly important in the hospital setting as emerging carriers of CPs, with KPC-
636 2, OXA-48 or VIM predominating depending on the geographic location (Arana et al., 2017;
637 Babiker et al., 2020; Yao et al., 2021). The presence of *bla*_{VIM-1} and *bla*_{NDM-1} has also been
638 reported in *Citrobacter freundii* from hospital H1 studied here (Atalić et al., 2013; Bedenić et
639 al., 2016). Our results also show the co-occurrence of two CPs (mostly *bla*_{KPC-2+NDM-1}) in
640 *Citrobacter* spp. which is consistent with some previous studies (Yao et al, 2021), or even three
641 different CPs such as *bla*_{KPC-2+NDM-1+VIM-1}, which to our knowledge has not been reported
642 before. This indicates that these *Citrobacter* spp. could be a relevant reservoir for potentially
643 transmissible carbapenem resistance in hospital wastewater. Moreover, in the present study,
644 carbapenem-resistant *K. pneumoniae*, which are an emerging public health problem in Croatia
645 and other EU countries, were found to contain predominantly *bla*_{OXA-48} and *bla*_{NDM-1} genes,
646 which frequently co-occur. This is consistent with previous findings showing that *bla*_{OXA-48} and
647 *bla*_{NDM-1} are the most frequently detected CP genes in clinical *K. pneumoniae* in Zagreb
648 hospitals (Bedenić et al, 2016, 2022). Isolation of this WHO priority pathogen from hospital
649 wastewater provides a secondary reservoir and possible transmission route for these bacteria to
650 natural waters and the community.

651 Molecular epidemiology using PFGE coupled with WGS identification of ARGs and
652 MLST was further performed on critical priority pathogens (WHO): ESBL- and CP-producing
653 *E. coli*, *K. pneumoniae*, and *Enterobacter* spp. Among the *E. coli* isolates, the ST of the largest
654 cluster could not be identified, possibly due to their environmental origin. In addition, WGS
655 analysis of a representative of this cluster revealed multiple ARGs for β-lactams, including
656 ESBL (*bla*_{CTX-M-15}, *bla*_{CTX-M-194}, *bla*_{TEM-116}) and CP genes (*bla*_{KPC-2}), and for other priority
657 antibiotics, as well as the presence of several plasmids, including those already associated with
658 the transmission of *bla*_{CTX-M-15} (IncFIA and IncFIB) or *bla*_{KPC-2} (IncR and Col440I) (Chen et al.,

659 2014; Nicolas-Chanoine et al., 2014; Rocha-Gracia et al., 2022). *E. coli* ST131 and ST541 were
660 among the most common sequence types detected in this study. Interestingly, ST131 has also
661 been found in human MDR isolates from hospitals in Croatia (Krilanović et al., 2020) and other
662 countries (Price et al., 2013), and in the environment including municipal wastewater (Hocquet
663 et al., 2016; Lopes et al., 2021). In this study, *E. coli* ST131 had ESBL (*bla*_{CTX-M-15+TEM116}) and
664 pAmpC genes (*bla*_{EBC}) and was found by WGS to have ARGs to other antibiotics such as
665 gentamycin and chloramfenicol and biocides (peroxides). It also contained the plasmid replicon
666 types IncFIA and IncFIB which have been associated with the spread of the *bla*_{CTX-M-15} gene
667 (Nicolas-Chanoine et al., 2014; Rocha-Gracia et al., 2022). In another ST, ST541, detected in
668 CP-producing *E. coli* strains, *bla*_{KPC-2} and ARGs to several other antibiotic classes were
669 detected. This ST is rare and has been detected in livestock in Asia (Chan et al., 2014; Qiu et
670 al., 2019).

671 Among the *K. pneumoniae* isolates examined in this study, ST101 was the most
672 prevalent multidrug-resistant clone, with phenotypic resistance to all β -lactams including
673 carbapenems. This ST was predominantly associated here with the *bla*_{OXA-48} gene which was
674 flanked by the IS4 family transposase IS10A, previously found predominantly in pOXA-48
675 plasmids (Hendrickx et al., 2021). This suggests that ST101 *K. pneumoniae* has the potential to
676 spread carbapenem resistance through horizontal transmission. In agreement with our results,
677 the presence of *bla*_{OXA-48} and *bla*_{NDM-1} in ST101 *K. pneumoniae* isolates has recently been
678 reported in Italian and Slovenian hospitals (Nucleo et al., 2020; Benulič et al., 2020). In
679 addition, this ST has also been detected in hospitals and treated hospital wastewater in Serbia
680 and Romania, respectively (Novović et al., 2017; Popa et al., 2021) Other STs detected in *K.*
681 *pneumoniae* isolates were ST16, associated with CP producers carrying *bla*_{OXA-48} and/or
682 *bla*_{NDM-1} and *bla*_{CTX-M-15} ESBL, and ST307, associated with ESBL producers carrying *bla*_{CTX-M-}
683 ₁₅ and *bla*_{SHV-28}. Previous studies from Croatia have reported the occurrence of *bla*_{NDM-1} or

684 *bla*_{OXA-48} in clinical ST16 *K. pneumoniae*, but the co-occurrence of *bla*_{NDM-1} and *bla*_{OXA-48} has
685 not yet been reported in this lineage in Croatia (Bedenić et al., 2016; Jelić et al., 2018; Kocsis
686 et al., 2016). In other countries, ST16 is frequently associated with co-occurrence of *bla*_{OXA-232}
687 and *bla*_{NDM-1} (Abe et al., 2022; Avolio et al., 2017; Espinal et al., 2019). Furthermore, ST307
688 has also been described in CTX-M-15-producing *K. pneumoniae*, which caused a nosocomial
689 outbreak in Germany (Haller et al., 2019). In addition, WGS showed that both ST16 and ST101
690 contained ARGs for several antibiotic classes other than β -lactams and several plasmid replicon
691 types, including IncFIA, IncFIB, and IncR that have previously been associated with the
692 carriage of *bla*_{CTX-M-15} in *K. pneumoniae* (Silva et al., 2022; Wyres et al., 2019). Apart from the
693 likely plasmid association, *bla*_{CTX-M-15} was flanked by insertion sequences and Tn3 type
694 transposon in our *K. pneumoniae* and *E. coli* isolates, highlighting the role of these platforms
695 in its further dissemination (Zhao and Hu, 2013; Grevskott et al., 2020).

696 The majority of *E. cloacae* cplx isolates analysed in this study were carbapenemase
697 producers belonging to ST277, which to our knowledge has not been previously detected in
698 humans or environmental samples. This ST was MDR with carbapenem and colistin resistance
699 being the most commonly detected resistance phenotypes. WGS showed that these isolates
700 harboured CP genes *bla*_{KPC-2} or *bla*_{KPC-2}+*bla*_{NDM-1} and several other ARGs for β -lactam and
701 other antibiotic classes and biocides, but no mobile colistin resistance genes. However, point
702 mutation analysis of these *E. cloacae* cplx isolates identified mutations in the *pmrA*, *pmrB*,
703 *phoP*, *phoQ* or *mgrB* genes that most likely confer the observed colistin resistance, suggesting
704 chromosomally associated resistance mechanisms. In addition, WGS showed that these isolates
705 contained a diverse plasmidome, including plasmid replicon types associated with the carriage
706 of *bla*_{KPC-2} (IncFII, IncN, IncP6, IncR, IncX5, and Col440I) (Chen et al., 2014; Souza et al.,
707 2019; Yao et al., 2017) or *bla*_{NDM-1} (IncFIB, IncN, and IncR) (Wu et al., 2019). This suggests
708 that these CP genes may spread further via HGT. Furthermore, *E. cloacae* isolates whose ST

709 classification could not be successfully identified (cluster B) contained *bla*_{VIM} and mobilizable
710 plasmids such as IncHI2, IncHI2A, and IncC, which are commonly associated with the
711 transmission of this gene (Arcari et al., 2020; Sadek et al., 2020). The *bla*_{VIM} gene was
712 genetically linked to several ARGs for other classes of antibiotics or antiseptics in these isolates,
713 suggesting possible common transmission of these genes via HGT. Finally, a ST501 *E. kobei*
714 isolate that had previously successfully colonized and persisted in hospital sinks and plumbing
715 (Aranega-Bou et al., 2021), was phenotypically identified here as PDR. This was supported by
716 the presence of a variety of ARGs, including the carbapenemases KPC-2 and NDM-1, which
717 could be associated with the detected plasmids IncN and IncR, respectively (Chen et al., 2014;
718 Gamal et al., 2016; Wang et al., 2018). Finally, the analysis of the genomic context of *bla*_{KPC-2}
719 showed that *Enterobacter* isolates carried this gene as part of a non-Tn4401 transposon, as also
720 reported in clinical *Enterobacter* isolates from Colombia (De La Cadena et al., 2018) and
721 environmental *Klebsiella* isolates from Brazil (Janssen et al., 2021), suggesting the potential for
722 mobilization.

723

724 **5. Conclusions**

725 The results of this study, which is the first of its kind in Croatia, show that the wastewater
726 from the two major hospitals in Zagreb contains relatively high levels of coliform bacteria
727 resistant to 3rd generation cephalosporins and carbapenems, as well as clinically significant
728 ESBL and CP genes. Of concern is the presence of the multidrug-resistant WHO priority
729 pathogens with both intrinsic (point mutations involved in colistin resistance) and acquired
730 resistance mechanisms (ESBL and carbapenemase) previously reported in patients from local
731 hospitals as well. So there is a possibility that these pathogenic strains and antibiotic-resistant
732 strains can be transmitted into the water systems and then back to humans and animals.
733 Effective treatment of hospital wastewater with advanced treatment methods such as UV and

734 ozone treatments must therefore be ensured to reduce or stop the spread of ARB and ARGs of
735 clinical concern in the natural environment.

736

737 **Acknowledgments**

738 This work was funded by the Croatian Science Foundation under project number IP-
739 2019-04-5539 and in part by a Croatian-Austrian bilateral project. We thank hospital staff for
740 providing wastewater samples from two collection sites, and to Dr. Stela Križanović for
741 assistance with sampling. We warmly acknowledge Dr. Damiano Cacace for providing
742 standards for *bla*_{TEM} and *bla*_{CTX-M-32} qPCR assays and Dr. Thomas Schwartz for assistance with
743 qPCR quantification of enterococci. We also thank Dr. Marija Gužvinec for providing positive
744 bacterial controls for carbapenemase genes and Silvia Schönthaler for help with library
745 preparation and whole genome sequencing.

746

747 **6. References**

748 Abe, R., Akeda, Y., Takeuchi, D., Sakamoto, N., Sugawara, Y., Yamamoto, N., Kerdsin, A.,
749 Matsumoto, Y., Motooka, D., Leolerd, W., Santanirand, P., Suzuki, M., Shibayama, K.,
750 Tomono, K., Iida, T., Hamada, S., 2022. Clonal dissemination of carbapenem-resistant
751 *Klebsiella pneumoniae* ST16 co-producing NDM-1 and OXA-232 in Thailand. JAC-AMR
752 4: 1–5. <https://doi.org/10.1093/jacamr/dlac084>

753 Alexander, J., Hembach, N., Schwartz, T., 2022. Identification of critical control points for
754 antibiotic resistance discharge in sewers. Sci. Total Environ. 820: 153186.
755 <https://doi.org/10.1016/j.scitotenv.2022.153186>

756 Arana, D.M., Ortega, A., González-Barberá, E., Lara, N., Bautista, V., Gómez-Ruíz, D., Sáez,
757 D., Fernández-Romero, S., Aracil, B., Pérez-Vázquez, M., Campos, J., Oteo, J., Gómez-

758 Alfaro, I., Aznar, J.E., Cercenado, E., López-Urrutia, L., García-Picazo, L., López-Calleja,
759 A.I., Sánchez-Romero, I., Zamarrón-Fuertes, P., Leiva, J., Alós, J.I., Solís, S., de Miguel,
760 M.D., Hernández, B., Romanyk, J., Delgado-Iribarren, A., Fernández, E.O., Trujillo, G.,
761 Torroba, L., Hernández Almaraz, J.L., Remacha Esteras, M.A., Salso, S., Gil, Y.,
762 Rodríguez-Conde, I., Alarcón, T., 2017. Carbapenem-resistant *Citrobacter* spp. isolated in
763 Spain from 2013 to 2015 produced a variety of carbapenemases including VIM-1, OXA-
764 48, KPC-2, NDM-1 and VIM-2. J. Antimicrob. Chemother. 72: 3283–3287.
765 <https://doi.org/10.1093/jac/dkx325>

766 Aranega-Bou, P., Ellaby, N., Ellington, M.J., Moore, G., 2021. Migration of *Escherichia coli*
767 and *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Enterobacter cloacae*
768 through wastewater pipework and establishment in hospital sink waste traps in a laboratory
769 model system. Microorganisms 9: 1868. <https://doi.org/10.3390/microorganisms9091868>

770 Arcari, G., Di Lella, F.M., Bibbolino, G., Mengoni, F., Beccaccioli, M., Antonelli, G., Faino,
771 L., Carattoli, A., 2020. A multispecies cluster of VIM-1 carbapenemase-producing
772 *Enterobacterales* linked by a novel, highly conjugative, and broad-host-range IncA
773 plasmid forebodes the reemergence of VIM-1. Antimicrob. Agents Chemother. 64:
774 e02435-19. <https://doi.org/10.1128/AAC.02435-19>

775 Atalić, V. Z., Bedenić, B., Kocsis, E., Mazzariol, A., Sardelić, S., Barišić, M., Plečko V.,
776 Bošnjak, Z., Mijač, M., Jajić, I., Vranić-Ladavac, M., Cornaglia, G. (2014). Diversity of
777 carbapenemases in clinical isolates of *Enterobacteriaceae* in Croatia - the results of a
778 multicentre study. CIM 20: O894-O903. <https://doi.org/10.1111/1469-0691.12635>

779 Avolio, M., Vignaroli, C., Crapis, M., Camporese, A., 2017. Co-production of NDM-1 and
780 OXA-232 by ST16 *Klebsiella pneumoniae*, Italy, 2016. Future Microbiol. 12: 1119–1122.
781 <https://doi.org/10.2217/fmb-2017-0041>

782 Aziz, R.K., Bartels, D., Best, A.A., DeJongh, M., Disz, T., Edwards, R.A., Formsma, K.,
783 Gerdes, S., Glass, E.M., Kubal, M., Meyer, F., Olsen, G.J., Olson, R., Osterman, A.L.,
784 Overbeek, R.A., McNeil, L.K., Paarmann, D., Paczian, T., Parrello, B., Pusch, G.D., Reich,
785 C., Stevens, R., Vassieva, O., Vonstein, V., Wilke, A., Zagnitko, O., 2008. The RAST
786 server: rapid annotations using subsystems technology. *BMC Genomics* 9: 75.
787 <http://dx.doi.org/10.1186/1471-2164-9-75>.

788 Babiker, A., Evans, D.R., Griffith, M.P., McElheny, C.L., Hassan, M., Clarke, L.G., Mettus,
789 R.T., Harrison, L.H., Doi, Y., Shields, R.K., Van Tyne, D., 2020. Clinical and genomic
790 epidemiology of carbapenem-nonsusceptible *Citrobacter* spp. at a tertiary health care
791 center over 2 decades. *J. Clin. Microbiol.* 58: e00275-20.
792 <https://doi.org/10.1128/JCM.00275-20>

793 Barišić, I., Mitteregger, D., Hirschl, A.M., Noehammer, C., Wiesinger-Mayr, H., 2014. High
794 diversity of beta-lactamases in the general hospital vienna verified by whole genome
795 sequencing and statistical analysis. *Infect. Genet. Evol.* 27: 408–417.
796 <https://doi.org/10.1016/j.meegid.2014.08.014>

797 Bedenić, B., Sardelić, S., Luxner, J., Bošnjak, Z., Varda-Brkić, D., Lukić-Grlić, A., Mareković,
798 I., Frančula-Zaninović, S., Krilanović, M., Šijak, D., Grisold, A., Zarfel, G., 2016.
799 Molecular characterization of class b carbapenemases in advanced stage of dissemination
800 and emergence of class D carbapenemases in *Enterobacteriaceae* from Croatia. *Infect.*
801 *Genet. Evol.* 43: 74–82. <https://doi.org/10.1016/j.meegid.2016.05.011>

802 Bedenić, B., Likić, S., Žižek, M., Bratić, V., D'Onofrio, V., Cavrić, G., Pavliša, G., Vodanović,
803 M., Gyssens, I., Barišić, I. (2022). Causative agents of bloodstream infections in two
804 Croatian hospitals and their resistance mechanisms. *J. Chemother.* 1-11.
805 <https://doi.org/10.1080/1120009X.2022.2104294>

806 Benulič, K., Pirš, M., Couto, N., Chlebowicz, M., Rossen, J.W.A., Zorec, T.M., Seme, K.,
807 Poljak, M., Lejko Zupanc, T., Ružić-Sabljić, E., Cerar, T., 2020. Whole genome
808 sequencing characterization of Slovenian carbapenem-resistant *Klebsiella pneumoniae*,
809 including OXA-48 and NDM-1 producing outbreak isolates. PLoS One 15: e0231503.
810 <https://doi.org/10.1371/journal.pone.0231503>

811 Bortolaia, V., Kaas, R. S., Ruppe, E., Roberts, M. C., Schwarz, S., Cattoir, V., ... & Aarestrup,
812 F. M., 2020. ResFinder 4.0 for predictions of phenotypes from genotypes. J. Antimicrob.
813 Chemother. 75: 3491-3500. <https://doi.org/10.1093/jac/dkaa345>

814 Bradford, P. A., 2001. Extended-spectrum β -lactamases in the 21st century: characterization,
815 epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:
816 933-951. doi: 10.1128/CMR.14.4.933-951.2001

817 Cantón, R., Akóva, M., Carmeli, Y., Giske, C.G., Glupczynski, Y., Gniadkowski, M.,
818 Livermore, D.M., Miriagou, V., Naas, T., Rossolini, G.M., Samuelsen, Ø., Seifert, H.,
819 Woodford, N., Nordmann, P., 2012. Rapid evolution and spread of carbapenemases among
820 *Enterobacteriaceae* in Europe. Clin. Microbiol. Infect. 18: 413–431.
821 <https://doi.org/10.1111/j.1469-0691.2012.03821.x>

822 Carattoli A. Animal reservoirs for extended spectrum β -lactamase producers. Clin Microbiol
823 Infect 2008;14:117–23.

824 Chan, J., Lo, W.-U., Chow, K.-H., Lai, E.L., Law, P.Y., Ho, P.-L., 2014. Clonal diversity of
825 *Escherichia coli* isolates carrying plasmid-mediated fosfomycin resistance gene *fosA3*
826 from livestock and other animals. Antimicrob. Agents Chemother. 58: 5638–5639.
827 <https://doi.org/10.1128/AAC.02700-14>

828 Chen, L., Mathema, B., Chavda, K.D., DeLeo, F.R., Bonomo, R.A., Kreiswirth, B.N., 2014.
829 Carbapenemase-producing *Klebsiella pneumoniae*: molecular and genetic decoding.
830 Trends Microbiol. 22: 686–696. <https://doi.org/10.1016/j.tim.2014.09.003>

831 Clifford, R.J., Milillo, M., Prestwood, J., Quintero, R., Zurawski, D.V., Kwak, Y.I., Waterman,
832 P.E., Lesho, E.P., Mc Gann, P., 2012. Detection of bacterial 16S rRNA and identification
833 of four clinically important bacteria by real-time PCR. PLoS One 7: 1–7.
834 <https://doi.org/10.1371/journal.pone.0048558>

835 D’Onofrio, V., Conzemius, R., Varda-Brkić, D., Bogdan, M., Grisold, A., Gyssens, I.C.,
836 Bedenić, B., Barišić, I., 2020. Epidemiology of colistin-resistant, carbapenemase-
837 producing *Enterobacteriaceae* and *Acinetobacter baumannii* in Croatia. Infect. Genet.
838 Evol. 81: 104263. <https://doi.org/10.1016/j.meegid.2020.104263>

839 De La Cadena, E., Correa, A., Muñoz, J.S., Rojas, L.J., Hernández-Gómez, C., Pallares, C.,
840 Perez, F., Bonomo, R.A., Villegas, M. V., 2018. Molecular characterisation of
841 carbapenem-resistant *Enterobacter cloacae* complex in Colombia: *bla*KPC and the
842 ‘changing landscape.’ J. Glob. Antimicrob. Resist. 13: 184–189.
843 <https://doi.org/10.1016/j.jgar.2017.12.008>

844 European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority
845 (EFSA), & European Medicines Agency (EMA), 2021. Third joint inter-agency report on
846 integrated analysis of consumption of antimicrobial agents and occurrence of antimicrobial
847 resistance in bacteria from humans and food-producing animals in the EU/EEA: JIACRA
848 III 2016-2018. EFSA J. 19: e06712. <https://doi:10.2903/j.efsa.2021.6712>

849 Espinal, P., Nucleo, E., Caltagirone, M., Mattioni Marchetti, V., Fernandes, M.R., Biscaro, V.,
850 Rigoli, R., Carattoli, A., Migliavacca, R., Villa, L., 2019. Genomics of *Klebsiella*

851 *pneumoniae* ST16 producing NDM-1, CTX-M-15, and OXA-232. Clin. Microbiol. Infect.
852 25, 385.e1-385.e5. <https://doi.org/10.1016/j.cmi.2018.11.004>

853 Flach, C. F., Hutinel, M., Razavi, M., Åhrén, C., & Larsson, D. J., 2021. Monitoring of hospital
854 sewage shows both promise and limitations as an early-warning system for carbapenemase-
855 producing *Enterobacterales* in a low-prevalence setting. Water Res. 200: 117261.
856 <https://doi.org/10.1016/j.watres.2021.117261>

857 Gamal, D., Fernández-Martínez, M., Salem, D., El-Defrawy, I., Montes, L.Á., Ocampo-Sosa,
858 A.A., Martínez-Martínez, L., 2016. Carbapenem-resistant *Klebsiella pneumoniae* isolates
859 from Egypt containing *bla*NDM-1 on IncR plasmids and its association with *rmtF*. Int. J.
860 Infect. Dis. 43: 17–20. <https://doi.org/10.1016/j.ijid.2015.12.003>

861 Gadsby, N. J., McHugh, M. P., Russell, C. D., Mark, H., Morris, A. C., Laurenson, I. F., Hill,
862 A. T., Templeton, K. E., 2015. Development of two real-time multiplex PCR assays for the
863 detection and quantification of eight key bacterial pathogens in lower respiratory tract
864 infections. Clin. Microbiol. Infect. 21: 788-e1. <https://doi.org/10.1016/j.cmi.2015.05.004>

865 Grevskott, D. H., Salvà-Serra, F., Moore, E. R., Marathe, N. P., 2020. Nanopore sequencing
866 reveals genomic map of CTX-M-type extended-spectrum β -lactamases carried by
867 *Escherichia coli* strains isolated from blue mussels (*Mytilus edulis*) in Norway. BMC
868 microbiology, 20: 1-10. doi: 10.1186/s12866-020-01821-8

869 González-Plaza, J. J., Blau, K., Milaković, M., Jurina, T., Smalla, K., & Udiković-Kolić, N.,
870 2019. Antibiotic-manufacturing sites are hot-spots for the release and spread of antibiotic
871 resistance genes and mobile genetic elements in receiving aquatic environments. Environ.
872 Int. 130: 104735. <https://doi.org/10.1016/j.envint.2019.04.007>

873 Gupta, G., Tak, V., & Mathur, P. (2014). Detection of AmpC β lactamases in gram-negative
874 bacteria. J. lab. physicians, 6(01): 001-006. 10.4103/0974-2727.129082

875 Haller, S., Kramer, R., Becker, K., Bohnert, J.A., Eckmanns, T., Hans, J.B., Hecht, J., Heidecke,
876 C.-D., Hübner, N.-O., Kramer, A., Klaper, K., Littmann, M., Marlinghaus, L., Neumann,
877 B., Pfeifer, Y., Pfennigwerth, N., Rogge, S., Schaufler, K., Thürmer, A., Werner, G.,
878 Gatermann, S., 2019. Extensively drug-resistant *Klebsiella pneumoniae* ST307 outbreak,
879 north-eastern Germany, June to October 2019. *Eurosurveillance* 24: 1–6.
880 <https://doi.org/10.2807/1560-7917.ES.2019.24.50.1900734>

881 Hassoun-Kheir, N., Stabholz, Y., Kreft, J.U., de la Cruz, R., Romalde, J.L., Nesme, J., Sørensen,
882 S.J., Smets, B.F., Graham, D., Paul, M., 2020. Comparison of antibiotic-resistant bacteria
883 and antibiotic resistance genes abundance in hospital and community wastewater: A
884 systematic review. *Sci. Total Environ.* 743: 140804.
885 <https://doi.org/10.1016/j.scitotenv.2020.140804>

886 Hendrickx, A.P.A., Landman, F., de Haan, A., Witteveen, S., van Santen-Verheувel, M.G.,
887 Schouls, L.M., 2021. *bla*OXA-48-like genome architecture among carbapenemase-
888 producing *Escherichia coli* and *Klebsiella pneumoniae* in the Netherlands. *Microb.*
889 *Genomics* 7: 5. <https://doi.org/10.1099/mgen.0.000512>

890 Hocquet, D., Muller, A., Bertrand, X., 2016. What happens in hospitals does not stay in
891 hospitals: antibiotic-resistant bacteria in hospital wastewater systems. *J. Hosp. Infect.* 93:
892 395–402. <https://doi.org/10.1016/j.jhin.2016.01.010>

893 Hooban, B., Joyce, A., Fitzhenry, K., Chique, C., Morris, D., 2020. The role of the natural
894 aquatic environment in the dissemination of extended spectrum beta-lactamase and
895 carbapenemase encoding genes: A scoping review. *Water Res.* 180: 1–12.
896 <https://doi.org/10.1016/j.watres.2020.115880>

897 Janssen, L., de Almeida, F.M., Damasceno, T.A.S., Baptista, R. de P., Pappas, G.J., de Campos,
898 T.A., Martins, V. de P., 2021. A novel multidrug resistant, non-Tn4401 genetic element-

899 bearing, strain of *Klebsiella pneumoniae* isolated from an urban lake with drinking and
900 recreational water reuse. *Front. Microbiol.* 12: 1–12.
901 <https://doi.org/10.3389/fmicb.2021.732324>

902 Jelic, M., Butic, I., Plecko, V., Cipris, I., Jajic, I., Bejuk, D., Koscak, I., Marinkovic, S., Pal,
903 M.P., Andrasevic, A.T., 2016. KPC-Producing *Klebsiella pneumoniae* Isolates in Croatia:
904 A Nationwide Survey. *Microb. Drug Resist.* 22: 662–667.
905 <https://doi.org/10.1089/mdr.2015.0150>

906 Jelić, M., Škrilin, J., Bejuk, D., Koščak, I., Butić, I., Gužvinec, M., Tambić-Andrašević, A., 2018.
907 Characterization of isolates associated with emergence of OXA-48-producing *Klebsiella*
908 *pneumoniae* in Croatia. *Microb. Drug Resist.* 24, 973–979.
909 <https://doi.org/10.1089/mdr.2017.0168>

910 Jelić, M., Hrenović, J., Dekić, S., Goić-Barišić, I., Tambić Andrašević, A., 2019. First evidence
911 of KPC-producing ST258 *Klebsiella pneumoniae* in river water. *J. Hosp. Infect.* 103: 147–
912 150. <https://doi.org/10.1016/j.jhin.2019.04.001>

913 Kazmierczak, K.M., Karlowsky, J.A., de Jonge, B.L.M., Stone, G.G., Sahn, D.F., 2021.
914 Epidemiology of carbapenem resistance determinants identified in meropenem-
915 nonsusceptible *Enterobacterales* collected as part of a global surveillance program, 2012
916 to 2017. *Antimicrob. Agents Chemother.* 65: e02000-20.
917 <https://doi.org/10.1128/AAC.02000-20>

918 Kehl, K., Schallenberg, A., Szekat, C., Albert, C., Sib, E., Exner, M., Zacharias, N., Schreiber,
919 C., Parčina, M., Bierbaum, G., 2022. Dissemination of carbapenem resistant bacteria from
920 hospital wastewater into the environment. *Sci. Total Environ.* 806: 151339.
921 <https://doi.org/10.1016/j.scitotenv.2021.151339>

922 Kocsis, E., Gužvinec, M., Butić, I., Krešić, S., Crnek, S.Š., Tambić, A., Cornaglia, G.,
923 Mazzariol, A., 2016. BlaNDM-1 Carriage on IncR Plasmid in *Enterobacteriaceae* strains.
924 *Microb. Drug Resist.* 22: 123–128. <https://doi.org/10.1089/mdr.2015.0083>

925 Krilanović, M., Tomić-Paradžik, M., Meštrović, T., Beader, N., Herljević, Z., Conzemius, R.,
926 Barišić, I., Vraneš, J., Elvedi-Gašparović, V., Bedenić, B., 2020. Extended-spectrum beta-
927 lactamases and plasmid diversity in urinary isolates of *Escherichia coli* in Croatia: a nation-
928 wide, multicentric, retrospective study. *Folia Microbiol. (Praha)*. 65: 649–667.
929 <https://doi.org/10.1007/s12223-019-00769-1>

930 Larsen M V, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak, L., Sicheritz-
931 Ponten, T., Ussery, D.W., Aaerstrup, F.M., Lund, O., 2012. Multilocus sequence typing of
932 total-genome-sequenced bacteria. *J Clin Microbiol.* 50: 1355–61.
933 <https://doi.org/10.1128/JCM.06094-11>

934 Larsson, D.G.J., Flach, C.-F., 2022. Antibiotic resistance in the environment. *Nat. Rev.*
935 *Microbiol.* 20: 257–269. <https://doi.org/10.1038/s41579-021-00649-x>

936 Lopes, R., Furlan, J.P.R., dos Santos, L.D.R., Gallo, I.F.L., Stehling, E.G., 2021. Colistin-
937 resistant *mcr-1*-positive *Escherichia coli* ST131-H22 carrying *bla*CTX-M-15 and *qnrB19*
938 in agricultural soil. *Front. Microbiol.* 12: 1–12. <https://doi.org/10.3389/fmicb.2021.659900>

939 Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G.,
940 Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D.L., Rice, L.B.,
941 Stelling, J., Struelens, M.J., Vatopoulos, A., Weber, J.T., Monnet, D.L., 2012. Multidrug-
942 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert
943 proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.*
944 18: 268–281. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>

945 Manaia, C.M., Rocha, J., Scaccia, N., Marano, R., Radu, E., Biancullo, F., Cerqueira, F.,
946 Fortunato, G., Iakovides, I.C., Zammit, I., Kampouris, I., Vaz-Moreira, I., Nunes, O.C.,
947 2018. Antibiotic resistance in wastewater treatment plants: Tackling the black box.
948 Environ. Int. 115: 312–324. <https://doi.org/10.1016/j.envint.2018.03.044>

949 Nasri, E., Subirats, J., Sànchez-Melsió, A., Mansour, H. Ben, Borrego, C.M., Balcázar, J.L.,
950 2017. Abundance of carbapenemase genes (blaKPC, blaNDM and blaOXA-48) in
951 wastewater effluents from Tunisian hospitals. Environ. Pollut. 229: 371–374.
952 <https://doi.org/10.1016/j.envpol.2017.05.095>

953 Neidhöfer, C., Buechler, C., Neidhöfer, G., Bierbaum, G., Hannet, I., Hoerauf, A., Parčina, M.,
954 2021. Global distribution patterns of carbapenemase-encoding bacteria in a new light:
955 Clues on a role for ethnicity. Front. Cell. Infect. Microbiol. 11: 1–9.
956 <https://doi.org/10.3389/fcimb.2021.659753>

957 Nicolas-Chanoine, M.-H., Bertrand, X., Madec, J.-Y., 2014. *Escherichia coli* ST131, an
958 intriguing clonal group. Clin. Microbiol. Rev. 27: 543–574.
959 <https://doi.org/10.1128/CMR.00125-13>

960 Nordmann, P., Poirel, L., Dortet, L., 2012. Rapid detection of carbapenemase-producing
961 *Enterobacteriaceae*. Emerg. Infect. Dis. 18: 1503–1507.
962 <https://doi.org/10.3201/eid1809.120355>

963 Novović, K., Trudić, A., Brkić, S., Vasiljević, Z., Kojić, M., Medić, D., Ćirković, I., Jovčić, B.,
964 2017. Molecular epidemiology of colistin-resistant, carbapenemase-producing *Klebsiella*
965 *pneumoniae* in Serbia from 2013 to 2016. Antimicrob. Agents Chemother. 61: e02550-16.
966 <https://doi.org/10.1128/AAC.02550-16>

967 Nucleo, E., Marchetti, V.M., Mercato, A., Quatela, M., Villa, L., Migliavacca, R., 2020. OXA-
968 48 and NDM-1 *Klebsiella pneumoniae* of sequence type 101 from blood in a patient with
969 travel history abroad, Italy. *New Microbiol.* 43: 41–43. PMID: 32118283

970 Overbeek, R., Olson, R., Pusch, G.D., Olsen, G.J., Davis, J.J., Disz, T., Edwards, R.A., Gerdes,
971 S., Parello, B., Shukla, M., Vonstein, V., Wattam, A.R., Xia, F., Stevens, R., 2014. The
972 SEED and the rapid annotation of microbial genomes using subsystems technology
973 (RAST). *Nucleic Acids Res.* 42: D206–D214. DOI: 10.1093/nar/gkt1226

974 Paulus, G.K., Hornstra, L.M., Alygizakis, N., Slobodnik, J., Thomaidis, N., Medema, G., 2019.
975 The impact of on-site hospital wastewater treatment on the downstream communal
976 wastewater system in terms of antibiotics and antibiotic resistance genes. *Int. J. Hyg.*
977 *Environ. Health* 222: 635–644. <https://doi.org/10.1016/j.ijheh.2019.01.004>

978 Popa, L.I., Gheorghe, I., Barbu, I.C., Surleac, M., Paraschiv, S., Măruțescu, L., Popa, M.,
979 Pîrcălăbioru, G.G., Talapan, D., Niță, M., Streinu-Cercel, Anca, Streinu-Cercel, Adrian,
980 Oțelea, D., Chifiriuc, M.C., 2021. Multidrug resistant *Klebsiella pneumoniae* ST101 clone
981 survival chain from inpatients to hospital effluent after chlorine treatment. *Front.*
982 *Microbiol.* 11: 610296. <https://doi.org/10.3389/fmicb.2020.610296>

983 Price, L.B., Johnson, J.R., Aziz, M., Clabots, C., Johnston, B., Tchesnokova, V., Nordstrom, L.,
984 Billig, M., Chattopadhyay, S., Stegger, M., Andersen, P.S., Pearson, T., Riddell, K.,
985 Rogers, P., Scholes, D., Kahl, B., Keim, P., Sokurenko, E. V., 2013. The epidemic of
986 extended-spectrum- β -lactamase-producing *Escherichia coli* ST131 is driven by a single
987 highly pathogenic subclone, H30-Rx. *MBio* 4: e00377-13.
988 <https://doi.org/10.1128/mBio.00377-13>

989 Puljko, A., Milaković, M., Križanović, S., Kosić-Vukšić, J., Babić, I., Petrić, I., Maravić, A.,
990 Jelić, M., Udiković-Kolić, N., 2022. Prevalence of enteric opportunistic pathogens and

991 extended-spectrum cephalosporin- and carbapenem-resistant coliforms and genes in
992 wastewater from municipal wastewater treatment plants in Croatia. *J. Hazard. Mater.* 427:
993 128155. <https://doi.org/10.1016/j.jhazmat.2021.128155>

994 Qiu, J., Jiang, Z., Ju, Z., Zhao, X., Yang, J., Guo, H., Sun, S., 2019. Molecular and phenotypic
995 characteristics of *Escherichia coli* isolates from farmed minks in Zhucheng, China. *Biomed*
996 *Res. Int.* 2019: 1–12. <https://doi.org/10.1155/2019/3917841>

997 Rocha-Gracia, R. del C., Lozano-Zarain, P., Gutiérrez Cázarez, Z., Alonso, C.A., Brambila, E.,
998 Torres, C., Cortés-Cortés, G., 2022. IncFIB plasmids carrying the resistance gene *bla*CTX-
999 M-15 in ESBL-producing *Escherichia coli* clones from pediatric patients. *J. Infect. Dev.*
1000 *Ctries.* 16: 500–506. <https://doi.org/10.3855/jidc.15080>

1001 Rodríguez-Mozaz, S., Chamorro, S., Martí, E., Huerta, B., Gros, M., Sánchez-Melsió, A.,
1002 Borrego, C.M., Barceló, D., Balcázar, J. L., 2015. Occurrence of antibiotics and antibiotic
1003 resistance genes in hospital and urban wastewaters and their impact on the receiving river.
1004 *Water Res.* 69: 234-242. DOI: 10.1016/j.watres.2014.11.021

1005 Rozman, U., Duh, D., Cimerman, M., Turk, S.Š., 2020. Hospital wastewater effluent: hot spot
1006 for antibiotic resistant bacteria. *J. Water Sanit. Hyg. Dev.* 10: 171-178.
1007 <https://doi.org/10.2166/washdev.2020.086>

1008 Sadek, M., Nariya, H., Shimamoto, Toshi, Kayama, S., Yu, L., Shimamoto, Tadashi, 2020. First
1009 genomic characterization of *bla*VIM-1 and *mcr*-9- coharbouring *Enterobacter hormaechei*
1010 isolated from food of animal origin. *Pathogens* 9: 687.
1011 <https://doi.org/10.3390/pathogens9090687>

1012 Silva, C.P., Oliveira, C.J.B. de, Leite, E.L., Cibulski, S.P., Fernandes, M., Vasconcelos, P.C.,
1013 Dias, L.M., Silva, N.M.V. da, Garino Júnior, F., Fernandes, A.C. de C., 2022. CTX-M-15-

1014 producing *Klebsiella pneumoniae* ST273 associated with nasal infection in a domestic cat.
1015 J. Glob. Antimicrob. Resist. 28: 203–205. <https://doi.org/10.1016/j.jgar.2022.01.004>

1016 Souza, R.C. de, Dabul, A.N.G., Boralli, C.M. dos S., Zuvanov, L., Camargo, I.L.B. da C., 2019.
1017 Dissemination of *bla*KPC-2 in an NTEKPC by an IncX5 plasmid. Plasmid 106: 102446.
1018 <https://doi.org/10.1016/j.plasmid.2019.102446>

1019 Stoddard, S. F., Smith, B. J., Hein, R., Roller, B. R., Schmidt, T. M., 2015. *rrn* DB: improved
1020 tools for interpreting rRNA gene abundance in bacteria and archaea and a new foundation
1021 for future development. Nucleic Acids Res. 43: D593-D598.
1022 <https://doi.org/10.1093/nar/gku1201>

1023 Wang, J., Zeng, Z.-L., Huang, X.-Y., Ma, Z.-B., Guo, Z.-W., Lv, L.-C., Xia, Y.-B., Zeng, L.,
1024 Song, Q.-H., Liu, J.-H., 2018. Evolution and comparative genomics of F33:A–:B–
1025 plasmids carrying *bla*CTX-M-55 or *bla*CTX-M-65 in *Escherichia coli* and *Klebsiella*
1026 *pneumoniae* isolated from animals, food products, and humans in China. mSphere 3: 1–12.
1027 <https://doi.org/10.1128/mSphere.00137-18>

1028 Weisburg, W.G., Barns, S.M., Pelletier, D.A., Lane, D.J., 1991. 16S ribosomal DNA
1029 amplification for phylogenetic study. J. Bacteriol. 173: 697–703.
1030 <https://doi.org/10.1128/jb.173.2.697-703.1991>

1031 World Health Organization, 2019. Critically important antimicrobials for human medicine.

1032 Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., Zong, Z., 2019. NDM Metallo-beta-
1033 lactamases and their bacterial producers in health care settings. Clin. Microbiol. Rev. 32:
1034 e00115-18. <https://doi.org/doi.org/10.1128/CMR.00115-18>

1035 Wyres, K.L., Hawkey, J., Hetland, M.A.K., Fostervold, A., Wick, R.R., Judd, L.M., Hamidian,
1036 M., Howden, B.P., Löhr, I.H., Holt, K.E., 2019. Emergence and rapid global dissemination

1037 of CTX-M-15-associated *Klebsiella pneumoniae* strain ST307. J. Antimicrob. Chemother.
1038 74: 577–581. <https://doi.org/10.1093/jac/dky492>

1039 Yao, Y., Falgenhauer, L., Falgenhauer, J., Hauri, A.M., Heinmüller, P., Domann, E.,
1040 Chakraborty, T., Imirzalioglu, C., 2021. Carbapenem-resistant *Citrobacter* spp. as an
1041 emerging concern in the hospital-setting: results from a genome-based regional
1042 surveillance study. Front. Cell. Infect. Microbiol. 11: 1–12.
1043 <https://doi.org/10.3389/fcimb.2021.744431>

1044 Yao, Y., Lazaro-Perona, F., Falgenhauer, L., Valverde, A., Imirzalioglu, C., Dominguez, L.,
1045 Cantón, R., Mingorance, J., Chakraborty, T., 2017. Insights into a novel *blaKPC-2* -
1046 encoding IncP-6 plasmid reveal carbapenem-resistance circulation in several
1047 *Enterobacteriaceae* species from wastewater and a hospital source in Spain. Front.
1048 Microbiol. 8: 1–7. <https://doi.org/10.3389/fmicb.2017.01143>

1049 Zhang, L., Ma, X., Luo, L., Hu, N., Duan, J., Tang, Z., Zhong, R., Li, Y., 2020. The prevalence
1050 and characterization of extended-spectrum β -lactamase-and carbapenemase-producing
1051 bacteria from hospital sewage, treated effluents and receiving rivers. IJERPH 17: 1183.
1052 <https://doi.org/10.3390/ijerph17041183>

1053 Zhao, W. H., Hu, Z. Q., 2013. Epidemiology and genetics of CTX-M extended-spectrum β -
1054 lactamases in Gram-negative bacteria. Crit. Rev. Microbiol. 39: 79-101. DOI:
1055 10.3109/1040841X.2012.691460

1056

1057

1058

1059

1060 **Figure Captions**

1061 **Fig. 1.** Boxplot comparison of concentrations (CFU/mL) of total, presumptive CTX-R and CR
1062 *E. coli* (A) or non-*E. coli* coliforms (B) in wastewater from both hospitals. Boxes indicate
1063 median and quartiles, and whiskers represent minimum and maximum values. Asterisks
1064 indicate significant difference between seasons ($*p < 0.05$, multiple Welch's t-test).

1065
1066 **Fig. 2.** Relative abundance of ESBL (*bla*_{CTX-M-32} and *bla*_{TEM}) (A) and carbapenemase (CP)
1067 genes (*bla*_{OXA-48}, *bla*_{KPC-3}, *bla*_{NDM}, *bla*_{IMP}, and *bla*_{VIM}) (B) in wastewater from two hospitals
1068 during winter and summer sampling. A significant difference between gene abundance in
1069 samples from different seasons in each hospital was determined using an unpaired t-test and is
1070 indicated by asterisks ($**p < 0.01$; $***p < 0.001$, multiple unpaired t-test).

1071
1072 **Fig 3.** Quantification of *E. coli* (*yccT*), *K. pneumoniae* (*gltA*), *A. baumannii* (*secE*),
1073 *Enterococcus* spp. (23S rRNA) and total bacteria (16S rRNA) (cell equivalents (CE)/mL) from
1074 winter and summer samples in two hospitals. The boxes indicate the median and quartiles, and
1075 the whiskers represent the minimum and maximum values. Asterisks indicate significant
1076 difference between seasons ($*** p < 0.001$, multiple Welch's t-test).

1077
1078 **Fig. 4.** Percentage of ESBL- and carbapenemase-producing *Enterobacterales* (ESBL-E and
1079 CPE) isolates from hospital wastewater samples identified with an antibiotic resistance
1080 phenotype. AML: Amoxicillin; AMC: Amoxicillin/Clavulanic acid; CL: Cephalexin; CXM:
1081 Cefuroxime; CAZ: Ceftazidime; FEP: Cefepime; ETP: Ertapenem; IPM: Imipenem; MEM:
1082 Meropenem; GM: Gentamicin; SXT: Trimethoprim/Sulfamethoxazole; CIP: Ciprofloxacin;
1083 MDR: Multidrug-resistant, XDR: Extensively drug-resistant.

1084

1085 **Fig. 5.** Dendrogram generated with Bionumerics software showing cluster analysis of *Xba*I-
1086 PFGE patterns of (A) *Escherichia coli*, (B) *Klebsiella pneumoniae*, and (C) *Enterobacter* spp.
1087 isolates along with their antibiotic resistance phenotypes and genotypes, and multilocus
1088 sequence types (MLST). Red squares represent resistance, yellow squares represent
1089 intermediate resistance, and green squares represent susceptibility to the indicated antibiotics
1090 (AML- ampicillin, AMC – ampicillin/clavulanic acid, FEP – cefepime, CAZ – ceftazidime,
1091 CXM – cefuroxime, CL – cefalexin, CIP- ciprofloxacin, ETP – ertapenem, GM – gentamicin,
1092 IPM- imipenem, MEM – meropenem, SXT – trimethoprim/sulfamethoxazole, COL –colistin).
1093 ID stands for the name of the isolate. ND indicates that a MLST could not be completely
1094 identified. Medium indicates the selective antibiotic (CTX – cefotaxime or CARB –
1095 carbapenem) contained in the culture medium. Isolates selected for whole genome sequencing
1096 are underlined.

1097

1098 **Fig 6.** Schematic presentation of the genetic environment of ESBL (*bla*_{CTX-M}) and
1099 carbapenemase genes (*bla*_{OXA-48}, *bla*_{KPC-2} and *bla*_{VIM-1}). Numbers (1-3) denote predicted regions
1100 for cefepime resistance (1), aztreonam resistance (2), ciprofloxacin resistance (3), and mannose-
1101 1-phosphate guanylytransferase (4). *STND*- sequence type could not be completely identified.
1102 Analyses were performed using RAST annotation and the Gene Graphics web application
1103 (<https://genegraphics.net>).

1104